[Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination]. / COVID-19 Enfeksiyonu Geçirmeyen 60 Yas Üstü Kisilerde CoronaVac ve Pfizer-BioNTech Asisi Sonrasi IgA Antikor Yaniti Karsilastirilmasi.

The formation rate, magnitude, and duration of the antibody-mediated humoral immune response that develops against different viral proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are considered important in vaccine success. It is known that the response to vaccinations decreases due to immunosenescence in older adults. This study was aimed to investigate the levels of serum IgA response at 1st and 3rd month after vaccination of people over 60 years old who were immunized with CoronaVac and Pfizer-BioNTech. A total of 35 people living in the North Cyprus who have not previously had COVID-19 infection were included in the study. After the 2nd dose of vaccination, serum IgA levels were measured after the 1st and 3rd month with the anti-SARS-CoV-2 IgA (Euroimmun, Lubeck, Germany) kit. The statistical significance was determined as 0.05 in the whole study. SPSS and GraphPad Prism software were used for calculations, analyses and graphs. The possible effect of demographic variables on serum IgA level was compared between the vaccine groups and it was found that there was no statistically significant difference between them. For the IgA titer-positive individuals who had been vaccinated with the Pfizer-BioNTech vaccine, for both 1st and 3rd months were observed to be higher than CoronaVac vaccinated IgA titer-positive individuals. In individuals who received the CoronaVac vaccine, there was a statistically significant change in serum IgA levels between 1st and 3rd months, but there was no statistically significant change in the Pfizer-BioNTech vaccine administered group. When the Pfizer/BioNTech and CoronaVac vaccines were compared with each other in terms of serum IgA antibody titers, it was found that the mean serum IgA levels of the individuals in the Pfizer/BioNTech group were statistically higher at the 1st and 3rd months than the CoronaVac group. Serum IgA titers in both vaccine groups were statistically significantly decreased from 1st month to 3rd month. This study showed that the Pfizer/BioNTech vaccine induced higher SARS-CoV-2 specific serum IgA antibodies than the CoronaVac vaccine and remained seropositive for a longer time in individuals aged 60 years and older. It is believed that the serum IgA levels that were determined may not reflect the serum IgA levels. However, these findings support the studies in other literature, showing that the Pfizer-BioNTech mRNA vaccine induces higher SARS-CoV-2 specific serum IgA antibodies than the inactive CoronaVac vaccine and that it remains seropositive for a longer period of time. This study is important as it is the first study to compare the SARS-CoV-2 IgA antibody responses of individuals over 60 years of age in the Turkish Republic of Northern Cyprus in two different vaccine groups.

Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older.

INTRODUCTION: A vaccine against coronavirus disease 2019 (COVID-19) is critically needed for older adults because of the increased morbidity and mortality rates. METHODOLOGY: In this prospective study, we analysed the titre magnitude of the IgG antibodies directed against the SARS-CoV-2 Spike Protein S1 (S1-RBD) antigen in both CoronaVac and Pfizer-BioNTech groups. The samples were tested to detect antibodies that bind to the receptor-binding domain of the spike protein of SARS-CoV-2 using the Enzyme-Linked Immunosorbent Assay (ELISA) technique with SARS-CoV-2 IgG II Quant. The cut-off value was > 50 AU/mL. GraphPad Prism software was used. Statistical significance was defined at p < 0.05. RESULTS: The CoronaVac group (12 females, 13 males) had a mean age of 69.64 ± 1.38 years. The Pfizer-BioNTech group (13 males, 12 females) had a mean age of 72.36 ± 1.44 years. The anti- S1-RBD titre decrease rate from the 1st to the 3rd month for CoronaVac and Pfizer-BioNTech groups was 74.31% and 86.48%, respectively. There was no statistically significant difference in the antibody titre between the 1st month and 3rd month for the CoronaVac group. However, there was a significant difference between the 1st and 3rd month in the Pfizer-BioNTech group. In addition, there was no statistically significant difference in the genders between the 1st and 3rd month of the antibody titres for both the CoronaVac Pfizer-BioNTech group. CONCLUSIONS: The levels of anti-S1-RBD, the preliminary outcome data of our study, represents one piece of the puzzle of humoral response and duration of vaccination protection.

High fetal bisphenol A exposure enhances IL22 secretion: A proinflammatory cytokine.

BACKGROUND: Bisphenol A (BPA) is an industrial product, widely used in human consumed types of equipment that can be transmitted orally, by inhalation or through dermal absorption and is detectable in many body fluids including cord blood. A correlation between BPA concentration in maternal serum and cord blood has been demonstrated previously, suggesting a possible transfer of BPA via the transplacental path. OBJECTIVE: Our objective is to determine the impact of cord blood BPA level on cytokine responses. METHODS: In this cross-sectional study, healthy pregnant women who delivered healthy newborns followed by the Obstetrics and Gynecology Department between September 2016 to June 2017 were enrolled. Cord blood samples were obtained and BPA and IL4, IL5, IL10, IL17, IL22, IFN gama and TGF beta levels were studied by ELISA. RESULTS: Among 197 deliveries, 176 of them were included in the study. Due to lack of cut-off value, BPA levels were stratified as percentiles. No statistically significant difference was detected in comparison of cytokine levels based on BPA concentrations below and above the 25th and 50th percentiles. Significantly higher IL22 levels (p = 0.007) and increased ratio of IL22/TGFß (p = 0.04) were detected in those with BPA level above 75th percentile (>19.16 ng/ml) compared to the below group. CONCLUSIONS: This in vivo real-life study demonstrated that very high BPA levels in cord blood of expectant mothers enhances IL22 secretion in cord blood which is a proinflammatory cytokine. Studies evaluating long term immunological effects on those highly exposed newborns are necessitated.

Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: implications in health and disease.

Butyrylcholinesterase (BChE) is a serine esterase that plays a role in the detoxification of natural as well as synthetic ester-bond-containing compounds. Alterations in BChE activity are associated with a number of diseases. Cholinergic system abnormalities in particular are correlated with the formation of senile plaques in Alzheimer's disease (AD), and administration of cholinesterase inhibitors is a common therapeutic approach used to treat AD. Here, our aim was to study the interaction between BChE and fluoxetine. Molecular docking simulations revealed that fluoxetine penetrated deep into the active-site gorge of BChE and that it was engaged in stabilizing noncovalent interactions with multiple subsites. In substrate kinetic studies, the Vm, Km, kcat and kcat/Km values were found to be 20.59 ± 0.36 U mg-1 protein, 194 ± 14 µM, 1.3 × 108 s-1 and 6.7 × 105 µM-1s-1, respectively. Based on inhibitory studies, fluoxetine appeared to inhibit BChE competitively, with an IC50 value of 104 µM and a Ki value of 36.3 ± 4.7 µM. Overall, both the low Ki value and the high number of BChE-fluoxetine interactions suggest that fluoxetine is a potent inhibitor of BChE, although in vivo mechanisms for the direct effects of BChE inhibition on various pathologies remain to be further investigated.

Evaluation of Dose Dependent Maternal Exposure to Bisphenol A on Thyroid Functions in Newborns.

Bisphenol A (BPA) is an endocrine-disrupting chemical compound that is mainly used in industrial products as packaging and plastics. It usually transmits to humans via oral route from food-contact material. BPA has demonstrated to be found in body fluids with a higher amount of fetal tissues due to bio-accumulation. Although it has been reported to affect the endocrine system, results on thyroid functions of newborns are conflicting. The aim of the present study is to demonstrate the effect of different levels of BPA in cord blood on the thyroid functions of newborns, according to gender. METHODS: The study population included 88 newborns. The BPA levels, Thyroid stimulating hormone (TSH) and free thyroxine (fT4) levels of cord blood were measured. In addition, SPINA-GT (thyroid' incretory capasity), TSH Index (TSHI), standardized TSHI (sTSHI) were calculated and demographic characteristics of participants were noted. RESULTS: The mean of cord blood BPA was 4.934 ± 2.33 ng/mL. When evaluated according to quantiles of BPA, no association was found between BPA and thyroid hormone levels, as well as, SPINA-GT, TSHI, sTSHI in both genders. CONCLUSION: Although BPA has been shown to contaminate cord blood, no significant effect was detected on thyroid hormones, SPINA-GT, TSHI and sTSHI. Further investigations with larger study populations are warranted.